in vitro
PFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment potently decreases the LRRK2-pSer935/total LRRK2 ratio, with no significant adverse effects.
animal Model: Female Sprague Dawley rats (NTac:SD) weighed 225-250 g.
Dosage: 4 mg/kg and 7.5 mg/kg (pharmacokinetics and pharmacodynamics).
Administration: Orally BID for 10-12 weeks.
Result: The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing.
The terminal bodyweights exhibited no significant changes.
